Trial Profile
Effect of Saxagliptin in Addition to Dapagliflozin and Metformin on Insulin Resistance, Islet Cell Dysfunction, and Metabolic Control in Subjects With Type 2 Diabetes Mellitus on Previous Metformin Treatment
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Saxagliptin (Primary) ; Dapagliflozin; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 26 Sep 2016 Status changed from recruiting to completed.
- 01 Aug 2016 Planned End Date changed from 1 Aug 2016 to 1 Oct 2016.
- 01 Aug 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Oct 2016.